No price history available.
Key financial summary
Financials in BRL| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | BRLm | 1,182 | 1,366 | 1,407 | 1,373 | 1,754 | 1,702 | N/A | N/A |
| Operating profit | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | BRLm | 254 | 325 | 363 | 250 | 217 | 295 | N/A | N/A |
| EPS reported | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | BRLm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | BRL | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in BRL| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Blau Farmacêutica S.A. operates as a pharmaceutical enterprise, supplying private label medications across Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. Its extensive product portfolio encompasses a broad spectrum of therapeutic areas, including immunology, hematology, oncology, nephrology, specialized treatments, and antibiotics. The company's offerings also extend to biological drugs, oral and injectable therapies for cancer, specialized treatments for infectious diseases, and a range of prescription and over-the-counter products like dermo-medicines and contraceptives, catering to both retail and non-retail markets. Additionally, Blau provides pharmaceuticals derived from blood, biological and biotechnological agents, and antiretroviral drugs. Its client base includes hospitals, private medical clinics, chemotherapy and hemodialysis centers, and public health institutions. Established in 1987, the firm's corporate headquarters are situated in Cotia, Brazil.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Blau Farmacêutica S.A. operates as a pharmaceutical enterprise, supplying private label medications across Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. Its extensive product portfolio encompasses a broad spectrum of therapeutic areas, including immunology, hematology, oncology, nephrology, specialized treatments, and antibiotics. The company's offerings also extend to biological drugs, oral and injectable therapies for cancer, specialized treatments for infectious diseases, and a range of prescription and over-the-counter products like dermo-medicines and contraceptives, catering to both retail and non-retail markets. Additionally, Blau provides pharmaceuticals derived from blood, biological and biotechnological agents, and antiretroviral drugs. Its client base includes hospitals, private medical clinics, chemotherapy and hemodialysis centers, and public health institutions. Established in 1987, the firm's corporate headquarters are situated in Cotia, Brazil.